{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/XENE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T01:26:03.948Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9142,"canonical_name":"Xenon Pharmaceuticals Inc.","cik":"0001582313","uei":null,"lei":null,"duns":null,"ticker":"XENE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":45,"clinical":4},"count":49,"timeline":[{"ts":"2026-10-01","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-10-01","url_slug":"/sec/cik-0001582313/4/0001193125-26-409999","accession_number":"0001193125-26-409999","importance":30},{"ts":"2026-08-31","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-08-31","url_slug":"/sec/cik-0001582313/4/0001193125-26-377309","accession_number":"0001193125-26-377309","importance":30},{"ts":"2026-08-28","kind":"sec.filing","form_type":"144","title":"144 — Xenon Pharmaceuticals Inc. — 2026-08-28","url_slug":"/sec/cik-0001582313/144/0001950047-26-008816","accession_number":"0001950047-26-008816","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"144","title":"144 — Xenon Pharmaceuticals Inc. — 2026-08-13","url_slug":"/sec/cik-0001582313/144/0001193125-26-349336","accession_number":"0001193125-26-349336","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-08-13","url_slug":"/sec/cik-0001582313/4/0001193125-26-349351","accession_number":"0001193125-26-349351","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xenon Pharmaceuticals Inc. — 2026-08-13","url_slug":"/sec/cik-0001582313/schedule-13g-a/0000902219-26-000248","accession_number":"0000902219-26-000248","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xenon Pharmaceuticals Inc. — 2026-08-07","url_slug":"/sec/cik-0001582313/schedule-13g-a/0000315066-26-002245","accession_number":"0000315066-26-002245","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Xenon Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001582313/10-q/0001193125-26-338244","accession_number":"0001193125-26-338244","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Xenon Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001582313/8-k/0001193125-26-338019","accession_number":"0001193125-26-338019","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xenon Pharmaceuticals Inc. — 2026-08-06","url_slug":"/sec/cik-0001582313/schedule-13g-a/0000315066-26-002171","accession_number":"0000315066-26-002171","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001582313/4/0001193125-26-262671","accession_number":"0001193125-26-262671","importance":30},{"ts":"2026-06-05","kind":"sec.form144","reporter":"GARY PATOU","title":"Director","shares":1322,"usd_value":70053,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001950047-26-005710","importance":40.014010556},{"ts":"2026-06-05","kind":"sec.form144","reporter":"GILLIAN CANNON","title":"Director","shares":1190,"usd_value":63058,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001950047-26-005712","importance":40.01261162},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"PATOU GARY","title":null,"shares":1322,"price_per_share":53.14,"usd_value":70251,"security_title":"Common Shares","importance":35.07025108},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Cannon Gillian","title":null,"shares":1190,"price_per_share":53.14,"usd_value":63237,"security_title":"Common Shares","importance":35.0632366},{"ts":"2026-06-05","kind":"sec.filing","form_type":"144","title":"144 — Xenon Pharmaceuticals Inc. — 2026-06-05","url_slug":"/sec/cik-0001582313/144/0001950047-26-005712","accession_number":"0001950047-26-005712","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/8-k/0001193125-26-255396","accession_number":"0001193125-26-255396","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/4/0001193125-26-256120","accession_number":"0001193125-26-256120","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/4/0001193125-26-256121","accession_number":"0001193125-26-256121","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/4/0001193125-26-256122","accession_number":"0001193125-26-256122","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/4/0001193125-26-256124","accession_number":"0001193125-26-256124","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8","title":"S-8 — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8/0001193125-26-255419","accession_number":"0001193125-26-255419","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255486","accession_number":"0001193125-26-255486","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255504","accession_number":"0001193125-26-255504","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255510","accession_number":"0001193125-26-255510","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255517","accession_number":"0001193125-26-255517","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255521","accession_number":"0001193125-26-255521","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255530","accession_number":"0001193125-26-255530","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255539","accession_number":"0001193125-26-255539","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255544","accession_number":"0001193125-26-255544","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255442","accession_number":"0001193125-26-255442","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — Xenon Pharmaceuticals Inc. — 2026-06-03","url_slug":"/sec/cik-0001582313/s-8-pos/0001193125-26-255452","accession_number":"0001193125-26-255452","importance":30},{"ts":"2026-06-01","kind":"sec.insider.f","reporter":"Svoronos Dawn","title":null,"shares":1416,"price_per_share":53.41,"usd_value":75629,"security_title":"Common Shares","importance":15.07562856},{"ts":"2026-06-01","kind":"sec.insider.f","reporter":"GANNON STEVEN","title":null,"shares":1416,"price_per_share":53.41,"usd_value":75629,"security_title":"Common Shares","importance":15.07562856},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"PATOU GARY","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Machado Patrick","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Svoronos Dawn","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Cannon Gillian","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"GAROFALO ELIZABETH A.","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"GANNON STEVEN","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Gover Justin D.","title":null,"shares":2645,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Xenon Pharmaceuticals Inc.","title":"A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05667142","excerpt":"[\"Primary Generalized Tonic-Clonic Seizures\"]","importance":60},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xenon Pharmaceuticals Inc. — 2026-05-15","url_slug":"/sec/cik-0001582313/schedule-13g-a/0000902664-26-002464","accession_number":"0000902664-26-002464","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Xenon Pharmaceuticals Inc. — 2026-05-15","url_slug":"/sec/cik-0001582313/schedule-13g-a/0000938206-26-000027","accession_number":"0000938206-26-000027","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Xenon Pharmaceuticals Inc.","title":"A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05716100","excerpt":"[\"Focal Onset Seizures\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Xenon Pharmaceuticals Inc.","title":"An Open-label Study of XEN1101 in Epilepsy","security_title":"PHASE3","status":"ENROLLING_BY_INVITATION","accession_number":"NCT05718817","excerpt":"[\"Focal Epilepsy\",\"Tonic-Clonic Seizures\"]","importance":60},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — Xenon Pharmaceuticals Inc. — 2026-05-13","url_slug":"/sec/cik-0001582313/4/0001193125-26-222369","accession_number":"0001193125-26-222369","importance":30},{"ts":"2026-05-12","kind":"sec.insider.m","reporter":"GANNON STEVEN","title":null,"shares":3500,"price_per_share":7.38,"usd_value":25830,"security_title":"Common Shares","importance":15.02583},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Xenon Pharmaceuticals Inc.","title":"A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07172516","excerpt":"[\"Bipolar Disorder\",\"Bipolar Depression\",\"Bipolar I Disorder\",\"Bipolar II Disorder\"]","importance":60}]}